英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
tarbogan查看　tarbogan　在百度字典中的解释百度英翻中〔查看〕
tarbogan查看　tarbogan　在Google字典中的解释Google英翻中〔查看〕
tarbogan查看　tarbogan　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • CAR T Cell Therapy for Relapsed Refractory Multiple Myeloma . . .
    ABECMA is a CAR (chimeric antigen receptor) T-cell therapy It is a prescription medicine made using your own white blood cells These white blood cells have been changed (genetically modified) to find and attack your multiple myeloma cells ABECMA is given as an intravenous (IV) infusion Before receiving your ABECMA infusion:
  • Abecma hits the mark in earlier-stage multiple myeloma
    Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its objectives in a phase 3 trial
  • Bristol Myers Squibb - U. S. FDA Approves Bristol Myers Squibb . . .
    Abecma was recently approved in Japan, Switzerland and the European Union for adult patients with triple-class exposed relapsed and or refractory multiple myeloma after two prior lines of therapy, making it the only CAR T cell therapy available globally for earlier lines of therapy for patients with triple-class exposed relapsed and or
  • FDA Approves First Cell-Based Gene Therapy for Adult Patients . . .
    The U S Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease
  • ABECMA (idecabtagene vicleucel) | International Myeloma . . .
    ABECMA® (idecabtagene vicleucel, also known as “ide-cel”) is the first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U S Food and Drug Administration (FDA) in March 2021 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy, including an





中文字典-英文字典  2005-2009